Full Text (PDF)
Indian Journal of Obstetrics and Gynecology 10(3):p 151-155, July-September 2022. | DOI: https://doi.org/10.21088/ijog.2321.1636.10322.18
Original Article
A Study on Correlation of Tumor Markers and Histopathology in Ovarian Mass
Nimi Chandra Babu, Vaishali Taralekar, Salil Barsode
Author Information
Licence:
Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
Indian Journal of Obstetrics and Gynecology 10(3):p 151-155, July-September 2022. | DOI: https://doi.org/10.21088/ijog.2321.1636.10322.18
How Cite This Article:
Nimi Chandra Babu, Vaishali Taralekar, Salil Barsode / A Study on Correlation of Tumor Markers and Histopathology in Ovarian Mass / Indian J Obstet Gynecol. 2022;10(3):151–155.Timeline
Received : March 21, 2022
Accepted : April 25, 2022
Published : September 30, 2022
Abstract
Background: Most ovarian cancers are detected in the late stages as there are nearly no clinical symptoms or signs at the early stage. Its high mortality rate has made it one of the most investigated fields in gynecological oncology. Aim: To study correlation between serum tumor markers and histopathology in diagnosed and operated cases of ovarian mass. Objectives: To study tumor marker levels in diagnosed and operated cases of ovarian mass and post operatively with the histopathology of said specimen. Settings and design: This is a prospective observational study carried out in a tertiary health care centre over 2 years from October 2019 to October 2021. Materials and Methods: The study population included 50 women diagnosed with an ovarian mass and operated for the same. After obtaining consent from the patient, detailed history was obtained, physical examination was done to examine the mass. Serum analysis for levels of tumor markers such as CA-125, b-HCG and Serum Lactate Dehydrogenase were assessed. Patient was investigated using ultrasound and if required MRI studies was also done. Post operatively, specimens were sent for histopathological studies. Conclusion: Among the tumor markers researched in this study, serum LDH can detect and predict the histological pattern of ovarian cancers as well as the malignant potential of the tumors. However, CA125 is able to predict only the malignant potential of the tumor. Beta hCG has no role in predicting the histology or malignant potential of tumors.
References
- 1. Maheshwari A, Kumar N, Gupta S, Rekhi B, Shylasree T S, Dusane R, Bajpai J, Ghosh J,Gulia S, DeodharK,Menon S, Popat P, Sable N, ThakurM,Kerkar R. Outcomes of advanced epithelial ovarian cancers treated with neoadjuvant chemotherapy. Indian J Cancer 2018;55:50-4
- 2. OberaignerW,Minicozzi P, Bielska-Lasota m, et al;Eurocare Working Group. Survival for ovarian cancer in Europe:the across-country variation did not shrink in the past decade.ActaOncol. 2012;51 (4):441-453
- 3. XiaoqingGuo, Guangzhi Liu, Isaiah G., et al. OverexpressionoftheβSubunitofHumanChorionic Gonadotropin Promotes the Transformation of Human Ovarian Epithelial Cells and Ovarian Tumorigenesis. The American Journal of Pathology 2011,3
- 4. WeiminWu,HaoGao,Xiaofeng, et al. β-hCG promotes epithelial ovarian cancer metastasis through ERK/MMP2 signaling pathway. Cell Cycle. 2018,1
Data Sharing Statement
There are no additional data available. All raw data and code are available upon request.
Funding
This research received no funding.
Author Contributions
All authors contributed significantly to the work and approve its publication.
Ethics Declaration
This article does not involve any human or animal subjects, and therefore does not require ethics approval.
Acknowledgements
We would like to express our gratitude to the patients, their families, and all those who have contributed to this study.
Conflicts of Interest
No conflicts of interest in this work.
About this article
Cite this article
Nimi Chandra Babu, Vaishali Taralekar, Salil Barsode / A Study on Correlation of Tumor Markers and Histopathology in Ovarian Mass / Indian J Obstet Gynecol. 2022;10(3):151–155.
Licence:
Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
| Received | Accepted | Published |
|---|---|---|
| March 21, 2022 | April 25, 2022 | September 30, 2022 |
DOI: https://doi.org/10.21088/ijog.2321.1636.10322.18
Keywords
Tumor markersOvarian massSearch for Similar Articles
Similar Articles
- Clinical Efficacy of Modified Pregnancy Unique Quantification of Emesis (PUQE Sc...
- Stress Associated with In Vitro Fertilization (IVF) in Women
- Dyslipidemia at 12-14 Weeks of Gestation for Predicting Development of Preeclamp...
- Association of Maternal Factors with Perinatal outcome of Growth Restricted Fetu...
- Comparison of Efficacy of Trans-Cervical Foleys Catheter and PGE2 Gel for Induct...
Article Level Metrics
Last UpdatedSunday 26 July 2026, 09:44:00 (IST)
2656
Accesses
11
421
00
Citations
NA
NA
NA
Download citation
Article Keywords
Keyword Highlighting
Highlight selected keywords in the article text.
Timeline
| Received | March 21, 2022 |
| Accepted | April 25, 2022 |
| Published | September 30, 2022 |
licence
Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
